Advertisement

European Child & Adolescent Psychiatry

, Volume 28, Issue 4, pp 557–570 | Cite as

Predictive utility of childhood diagnosis of ICD-10 hyperkinetic disorder: adult outcomes in the MTA and effect of comorbidity

  • L. Eugene ArnoldEmail author
  • Arunima Roy
  • Eric Taylor
  • Lily Hechtman
  • Margaret Sibley
  • James M. Swanson
  • John T. Mitchell
  • Brooke S. G. Molina
  • Luis A. Rohde
Original Contribution

Abstract

Diagnostic guidelines differ between DSM attention-deficit/hyperactivity disorder (ADHD) and ICD hyperkinetic disorder (HKD). Only 145 of 579 children age 7–9 in the Multimodal Treatment Study of ADHD (the MTA) with combined-type DSM-IV ADHD met criteria for ICD-10 HKD, because major internalizing comorbidities and more stringent symptom count/pervasiveness requirements excluded most. The 145 HKD had significantly better 14-month medication response than the rest. We explored whether HKD had greater adult symptom persistence and/or impairment than other ADHD. Multi-informant assessments were done for 16 years. We used the 12/14/16-year assessments, in young adulthood. The post-attrition 109 with baseline HKD had no greater adult persistence of ADHD symptoms/impairment than 367 without HKD, but had more cumulative stimulant use, more job losses, lower emotional lability, and fewer car crashes. However, those excluded for internalizing comorbidity but otherwise meeting HKD criteria had significantly more persistence. Only 6 of the 109 (5.5%) with baseline HKD met ICD-10 criteria for HKD in adulthood, compared to 25 of 367 (6.8%) without a childhood HKD diagnosis. Despite greater initial symptom severity, HKD had no worse 16-year young adult outcome than others, except for job losses, balanced by less emotional lability and fewer crashes. Comorbid internalizing disorder seems to have worse prognosis than initial severity/pervasiveness of ADHD symptoms.

Keywords

International classification of diseases (ICD) Diagnostic and statistical manual of mental disorders (DSM) Adult outcomes Attention-deficit/hyperactivity disorder (ADHD) Hyperkinetic disorder 

Notes

Acknowledgements

The Multimodal Treatment Study of Children with ADHD (MTA) was a National Institute of Mental Health (NIMH) cooperative agreement randomized clinical trial, continued under an NIMH contract as a follow-up study and finally under a National Institute on Drug Abuse (NIDA) contract. Collaborators from NIMH: Benedetto Vitiello, M.D., Joanne B. Severe, M.S., Peter S. Jensen, M.D. (currently at REACH Institute and University of Arkansas), L. Eugene Arnold, M.D., M.Ed. (currently at Ohio State University), Kimberly Hoagwood, Ph.D. (currently at Columbia); previous contributors from NIMH to the early phases: John Richters, Ph.D. (currently at National Institute of Nursing Research); Donald Vereen, M.D. (currently at NIDA). Principal investigators and co-investigators from the sites are: University of California, Berkeley/San Francisco: Stephen P. Hinshaw, Ph.D. (Berkeley), Glen R. Elliott, Ph.D., M.D. (San Francisco); Duke University: Karen C. Wells, Ph.D., Jeffery N. Epstein, Ph.D. (currently at Cincinnati Children’s Hospital), Desiree W. Murray, Ph.D.; previous Duke contributors: C. Keith Conners, Ph.D. (former PI); John March, M.D., M.P.H.; University of California, Irvine: James Swanson, Ph.D., Timothy Wigal, Ph.D.; previous contributor from UCLA to early phases: Dennis P. Cantwell, M.D. (deceased); New York University School of Medicine: Howard B. Abikoff, Ph.D.; Montreal Children’s Hospital/McGill University: Lily Hechtman, M.D.; New York State Psychiatric Institute/Columbia University/Mount Sinai Medical Center: Laurence L. Greenhill, M.D. (Columbia), Jeffrey H. Newcorn, M.D. (Mount Sinai School of Medicine). University of Pittsburgh: Brooke Molina, Ph.D., Betsy Hoza, Ph.D. (currently at University of Vermont), William E. Pelham, Ph.D. (PI for early phases, currently at Florida International University). Follow-up phase statistical collaborators: Robert D. Gibbons, Ph.D. (University of Illinois, Chicago); Sue Marcus, Ph.D. (Mt. Sinai College of Medicine); Kwan Hur, Ph.D. (University of Illinois, Chicago). Original statistical and design consultant: Helena C. Kraemer, Ph.D. (Stanford University). Collaborator from Office of Special Education Programs/US Department of Education: Thomas Hanley, Ed.D. Collaborator from Office of Juvenile Justice and Delinquency Prevention/Department of Justice: Karen Stern, Ph.D. We gratefully acknowledge Rachel Bergman’s assistance with manuscript handling.

Compliance with ethical standards

Conflict of interest

Dr. Arnold has received research funding from Forest, Lilly, Noven, Shire, Supernus, Roche, and YoungLiving, consulted with Pfizer, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Otsuka, Pfizer, Roche, Seaside Therapeutics, and Shire. Dr. Taylor has consulted for South London and Maudsley NHS Foundation Trust and received book royalties from Wiley Blackwell and Oxford University Press. Dr. Hechtman has received research support, served on advisory boards, and been a speaker for Lilly, GlaxoSmithKline, Ortho-Janssen, Purdue, Shire, and Ironshore, and received book royalties from Guilford, APA, John Hopkins, and Oxford University Press. Dr. Sibley receives royalties from Guilford Press. Dr. Swanson received support years from NLS Pharma and Medice expert board meetings. Dr. Mitchell received royalties from New Harbinger Press. Dr. Rohde was on speakers’ bureau and/or consulted for Eli-Lilly, Janssen-Cilag, Medice, Novartis and Shire, and received royalties from Oxford Press and ArtMed and travel awards to 2015 WFADHD and 2016 AACAP; Outpatient Programs chaired by him received unrestricted educational/research support from: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. Dr. Molina and Dr. Roy have no disclosures.

Supplementary material

787_2018_1222_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 21 kb)

References

  1. 1.
    Andrews G, Slade T, Peters L (1999) Classification in psychiatry: ICD-10 versus DSM-IV. Br J Psychiatry 174(1):3–5CrossRefGoogle Scholar
  2. 2.
    World Health Organization (2001) International Classification of Functioning, Disability and Health: ICF. World Health Organization, GenevaGoogle Scholar
  3. 3.
    American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub, Washington DCCrossRefGoogle Scholar
  4. 4.
    Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP (1998) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351(9100):429–433CrossRefGoogle Scholar
  5. 5.
    Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–442CrossRefGoogle Scholar
  6. 6.
    Lee SI, Schachar RJ, Chen SX, Ornstein TJ, Charach A, Barr C, Ickowicz A (2008) Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder. J Child Psychol Psychiatry 49(1):70–78CrossRefGoogle Scholar
  7. 7.
    Tripp G, Luk SL, Schaughency EA, Singh R (1999) DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. J Am Acad Child Adolesc Psychiatry 38(2):156–164CrossRefGoogle Scholar
  8. 8.
    Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Möbius HJ, Eisert HG (1998) Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 7(4):184–200CrossRefGoogle Scholar
  9. 9.
    Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski J, Buitelaar D, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):i7.  https://doi.org/10.1007/s00787-004-1002-x Google Scholar
  10. 10.
    Santosh PJ, Taylor E, Swanson J, Wigal T, Chuang S, Davies M, Vitiello B (2005) Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the multimodal treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 5(5):307–314CrossRefGoogle Scholar
  11. 11.
    Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Kraemer HC (1997) National institute of mental health collaborative multimodal treatment study of children with ADHD (the MTA): design challenges and choices. Arch Gen Psychiatry 54(9):865–870CrossRefGoogle Scholar
  12. 12.
    Hinshaw SP, March JS, Abikoff H, Arnold LE, Cantwell DP, Conners CK, Hoza B (1997) Comprehensive assessment of childhood attention-deficit hyperactivity disorder in the context of a multisite, multimodal clinical trial. J Atten Disord 1(4):217–234CrossRefGoogle Scholar
  13. 13.
    MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56(12):1073–1086CrossRefGoogle Scholar
  14. 14.
    MTA Cooperative Group (2004) National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113(4):762–769CrossRefGoogle Scholar
  15. 15.
    MTA Cooperative Group (2004) National Institute of Mental Health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113(4):754–761CrossRefGoogle Scholar
  16. 16.
    Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, Conners CK (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46(8):989–1002CrossRefGoogle Scholar
  17. 17.
    Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Elliott GR (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48(5):484–500CrossRefGoogle Scholar
  18. 18.
    Swanson JM, Arnold LE, Molina BS, Sibley MH, Hechtman LT, Hinshaw SP, Nichols Q (2017) Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58(6):663–678CrossRefGoogle Scholar
  19. 19.
    Swanson JM (2000). Swanson, Nolan, & Pelham (SNAP) ADHD rating scale. ADHD.netGoogle Scholar
  20. 20.
    Sibley MH, Swanson JM, Arnold LE, Hechtman LT, Owens EB, Stehli A, Jensen PS (2017) Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry 58(6):655–662CrossRefGoogle Scholar
  21. 21.
    Hechtman L, Swanson JM, Sibley MH, Stehli A, Owens EB, Mitchell JT, Abikoff HB (2016) Functional adult outcomes 16 years after childhood diagnosis of attention-deficit/hyperactivity disorder: MTA results. J Am Acad Child Adolesc Psychiatry 55(11):945–952CrossRefGoogle Scholar
  22. 22.
    Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME (2000) NIMH diagnostic interview schedule for children version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39(1):28–38CrossRefGoogle Scholar
  23. 23.
    Curran S, Newman S, Taylor E, Asherson P (2000) Hypescheme: an operational criteria checklist and minimum data set for molecular genetic studies of attention deficit and hyperactivity disorders. Am J Med Genet Part A 96(3):244–250CrossRefGoogle Scholar
  24. 24.
    Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB, Banaschewski T (2008) Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet Part B Neuropsychiatr Genet 147(8):1345–1354CrossRefGoogle Scholar
  25. 25.
    Conners CK, Erhardt D, Sparrow EP (1999) Conners’ adult ADHD rating scales (CAARS): technical manual. MHS, North TonawandaGoogle Scholar
  26. 26.
    Macey KD (2003) In: Conners CK, Erhardt D, Sparrow MA (eds) Conners’ adult ADHD rating scales (CAARS). Multihealth Systems, Inc., 1999, New YorkGoogle Scholar
  27. 27.
    Molina BSG, Pelham WE (2003) Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 112(3):497–507CrossRefGoogle Scholar
  28. 28.
    Molina BS, Hinshaw SP, Arnold L et al (2013) Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry 52(3):250–263CrossRefGoogle Scholar
  29. 29.
    Costa PT, McCrae RR (1992) NEO PI-R Professional manual. Psychological Assessment Resources, Odessa, FLGoogle Scholar
  30. 30.
    Jensen PS, Hoagwood KE, Roper M, Arnold LE, Odbert C, Crowe M, Newcorn J (2004) The services for children and adolescents–parent interview: development and performance characteristics. J Am Acad Child Adolesc Psychiatry 43(11):1334–1344CrossRefGoogle Scholar
  31. 31.
    Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, Elliott GR (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40(2):147–158CrossRefGoogle Scholar
  32. 32.
    Caye A, Spadini AV, Karam RG, Grevet EH, Rovaris DL, Bau CH, Kieling C (2016) Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry 25(11):1151–1159CrossRefGoogle Scholar
  33. 33.
    Roy A, Hechtman L, Arnold LE, Sibley MH, Molina BSG, Howard AL (2016) Childhood factors affecting persistence and desistence of ADHD symptoms in adulthood: results from the MTA. J Am Acad Child Adolesc Psychiatry 55(11):937–944CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • L. Eugene Arnold
    • 1
    Email author
  • Arunima Roy
    • 2
  • Eric Taylor
    • 3
  • Lily Hechtman
    • 4
  • Margaret Sibley
    • 5
  • James M. Swanson
    • 6
  • John T. Mitchell
    • 7
  • Brooke S. G. Molina
    • 8
  • Luis A. Rohde
    • 9
  1. 1.Department of Psychiatry and Behavioral HealthOhio State UniversityColumbusUSA
  2. 2.Division of Molecular PsychiatryUniversity Hospital WürzburgWürzburgGermany
  3. 3.Institute of Psychiatry Psychology and NeuroscienceKing’s College LondonLondonUK
  4. 4.McGill UniversityMontreal Children’s HospitalMontrealCanada
  5. 5.Department of Psychiatry and Behavioral HealthFlorida International UniversityMiamiUSA
  6. 6.Department of PediatricsUniversity of California IrvineIrvineUSA
  7. 7.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA
  8. 8.Departments of Psychiatry, Psychology, and PediatricsUniversity of PittsburghPittsburghUSA
  9. 9.Division of Child and Adolescent PsychiatryHospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul and National Institute of Developmental Psychiatry for Children and AdolescentsPorto AlegreBrazil

Personalised recommendations